{"nctId":"NCT01314716","briefTitle":"Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis","startDateStruct":{"date":"2011-04"},"conditions":["Bronchiectasis"],"count":274,"armGroups":[{"label":"AZLI-AZLI","type":"EXPERIMENTAL","interventionNames":["Drug: AZLI"]},{"label":"Placebo-AZLI","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: AZLI","Drug: Placebo"]}],"interventions":[{"name":"AZLI","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male/Female 18 years or older with non-CF bronchiectasis\n* Chronic sputum production on most days\n* Positive sputum culture for gram-negative organisms\n* Must have met lung function requirements\n\nExclusion Criteria:\n\n* History of CF\n* Hospitalized within 14 days prior to joining the study\n* Previous exposure to AZLI\n* Pregnant, breastfeeding, or unwilling to follow contraceptive measures for the study\n* Must have met liver and kidney function requirements\n* Continuous oxygen use of greater than 2 liters per minute (supplemental oxygen with activity and at night was allowed)\n* Treatment for nontuberculous mycobacteria infection or active mycobacterium tuberculosis infection within 1 year of enrollment\n* Other serious medical conditions.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in QOL-B Respiratory Symptoms Score at Day 28","description":"The mean (SD) change in the Respiratory Symptoms score on the Quality of Life Questionnaire-Bronchiectasis (QOL-B) was measured from baseline to the end of Course 1 (Day 28). The QOL-B respiratory symptoms score was transformed onto a scale of 0-100, with higher scores representing a better quality of life.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.2","spread":"17.13"},{"groupId":"OG001","value":"3.2","spread":"14.67"}]}]}]},{"type":"SECONDARY","title":"Change in QOL-B Respiratory Symptoms Score at Day 84","description":"The mean (SD) change in the Respiratory Symptoms score on the QOL-B was measured from baseline to the end of Course 2 (Day 84). The QOL-B respiratory symptoms score was transformed onto a scale of 0-100, with higher scores representing a better quality of life.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.6","spread":"16.44"},{"groupId":"OG001","value":"3.9","spread":"17.73"}]}]}]},{"type":"SECONDARY","title":"Time to Protocol-Defined Exacerbation (PDE)","description":"Protocol-defined exacerbation was defined as an acute worsening of respiratory disease that triggered the initiation of a non-study antibiotic meeting at least 3 major criteria, or 2 major and at least 2 minor criteria.\n\n* Major Criteria: increased sputum production; increased discoloration of sputum; increased dyspnea; increased cough\n* Minor Criteria: fever (\\> 38ยบ C) measured during clinic visit; increased malaise or fatigue; forced expiratory volume in 1 second (FEV1) (L) or forced vital capacity (FVC) decreased \\> 10% from baseline; new or increased hemoptysis","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":18,"n":135},"commonTop":["Cough","Sputum increased","Dyspnoea","Sputum discoloured","Fatigue"]}}}